AACR 2023

#AACR #AACR 2023 #Awards #Cancer immunotherapy #Cancer research #Immunology / Virology & Vaccines

Tuesday 18 April at AACR Annual Meeting 2023

DDW’s Megan Thomas rounds up highlights from Tuesday 17 April at AACR 2023, from AI and mathematical oncology to winners of the AACR James S Ewing-Thelma B Dunn Award for Outstanding Achievement in Pathology in Cancer Research. Clinical announcements Promising results for olaparib plus ceralasertib Today, results from the Phase… Read More

#News

Gene sequence
#AACR 2023 #Cancer research #Gene mutation #Genetics / genomics #Oncology #Whole genome sequencing

Exome sequencing proves current cancer risk testing is inadequate

Exome sequencing correctly identified individuals with cancer predisposition syndromes who would have been missed by current screening guidelines, according to results from the Tapestry clinical trial. Data presented at the AACR Annual Meeting 2023 showed that among individuals who consented to whole-exome sequencing and were identified… Read More

#Cancer Research #News #Trending News

Cancer cells
#AACR 2023 #Cancer research #Oncology #Paediatrics #Phase I trial #Solid tumours

Combo therapy may benefit some paediatric cancer patients

A combination of the PARP inhibitor olaparib (Lynparza) and the investigational ATR inhibitor ceralasertib showed clinical benefit in paediatric patients with solid tumours exhibiting DNA replication stress and/or DNA repair deficiencies, according to new data. The results from the Phase I portion of the Phase I/II… Read More

#Cancer Research #News

Histology slides
#AACR 2023 #AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Cancer research #Machine learning #Oncology

AI can predict the risk of distant recurrence in endometrial cancer

An investigational deep learning model requiring one histopathologic slide accurately predicted the risk of distant recurrence in patients with endometrial cancer, according to findings presented at the AACR Annual Meeting 2023. Endometrial cancer is the most common type of uterine cancer. While patients with early-stage uterine… Read More

#Cancer Research #News #Trending News

Tumour microenvironment
#AACR 2023 #Avacta #Cancer research #Oncology #Preclinical development #Solid tumours

Data shows new therapy successfully targets solid tumours

Avacta Group has presented pre-clinical data describing the novel pre|CISION proteasome inhibitor, AVA3996, at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Florida, US. Proteasome inhibitors are effective anti-cancer drugs that could benefit from application of our preICISION technology to expand their use. Read More

#Cancer Research #News

#AACR #AACR 2023 #Awards #Cancer immunotherapy #Cancer research #Immunology / Virology & Vaccines

Monday 17 April at AACR Annual Meeting 2023

DDW’s Megan Thomas rounds up highlights from Monday 16 April at AACR 2023, from promising trial results for colorectal cancer patients to updates on Biden’s Cancer Moonshot initiative. Clinical announcements  Data on colorectal cancer patients with African ancestry Today, data presented at the AACR Annual Meeting showed that genomic… Read More

#News

Teenage boy having vaccination
#AACR 2023 #Cancer research #HPV #Oncology #Vaccines

Awareness of the link between HPV and cancer has declined

Americans have become less aware that the human papillomavirus (HPV) causes cervical cancer in recent years, according to survey data presented at the AACR Annual Meeting 2023. Survey respondents also showed low awareness that HPV can cause anal, oral, and penile cancer. “Over 90%… Read More

#News

Myeloma cells
#AACR 2023 #Antibody #Cancer research #Immunotherapy #Myeloma #Oncology #T cell activation

Bispecific antibody has 90% response rate in multiple myeloma

Patients with relapsed or refractory multiple myeloma who were treated with the two highest doses of REGN5459, a bispecific antibody targeting BCMA and CD3, experienced a 90.5% overall response rate. This is according to results of a Phase I/II clinical trial presented at the AACR Annual… Read More

#Cancer Research #News #Trending News

Genetics
#AACR 2023 #Cancer research #Colorectal cancer #Genetics / genomics #Oncology

Patients of African heritage have fewer actionable mutations

Genomic profiling of patients who were treated for colorectal cancer showed that patients with African ancestry had fewer actionable mutations than patients with European ancestry. These patients were also less likely to qualify for treatment with immunotherapy, according to data presented at the AACR Annual Meeting… Read More

#Cancer Research #News #Trending News

#AACR #AACR 2023 #Awards #Cancer immunotherapy #Cancer research #Immunology / Virology & Vaccines #mRNA

Sunday 16 April at AACR Annual Meeting 2023

DDW’s Megan Thomas rounds up highlights from Sunday 16 April at AACR 2023, from promising trial results for a personalised mRNA-based cancer vaccine to winners of lifetime achievement awards. Opening plenary session Sunday’s opening plenary session borrowed its name from the Annual Meeting theme, “Advancing the Frontiers of Cancer Science… Read More

#News

Medical laboratory
#AACR 2023 #Cancer research #Cancer treatment #Oncology #Phase III trial #Rare cancers

Immune checkpoint inhibitor improved survival in rare cancer

The addition of pembrolizumab (Keytruda) to gemcitabine and cisplatin improved overall survival in patients with untreated metastatic or unresectable biliary tract cancer, according to results from the Phase III KEYNOTE-966 clinical trial. The results were presented at the AACR Annual Meeting 2023, held April 14-19 and… Read More

#Cancer Research #News

Lung cancer
#AACR 2023 #Cancer research #Cancer treatment #Lung cancer #Oncology #Phase III trial

Therapy represents ‘new treatment paradigm’ for lung cancer

Patients with treatment-naïve resectable non-small cell lung cancer (NSCLC) who received neoadjuvant durvalumab (Imfinzi) plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival (EFS) and pathological complete response (pCR) compared with those who received neoadjuvant chemotherapy alone. The results from the Phase III placebo-controlled AEGEAN… Read More

#Cancer Research #News #Trending News

Liver cancer
#AACR 2023 #Cancer research #Cancer treatment #Liver cancer #Oncology #Phase III trial

Results revealed for ‘practice-changing’ combination liver cancer therapy

Adjuvant therapy with atezolizumab (Tecentriq) and bevacizumab (Avastin) increased recurrence-free survival of patients with hepatocellular carcinoma (HCC) following surgical resection or ablation, according to the results from a Phase III trial. The results of the IMbrave050 clinical trial were presented at the AACR Annual Meeting 2023,… Read More

#Cancer Research #News

#AACR 2023 #Cancer research #Cancer vaccine #mRNA #mRNA-based vaccines #Oncology

Personalised mRNA cancer vaccine prolongs survival in melanoma

Personalised mRNA-based cancer vaccine mRNA-4157/V940, in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda) improved recurrence-free survival (RFS) compared with pembrolizumab alone in patients with high-risk melanoma. The clinical benefit was observed regardless of the tumour mutational burden (TMB) status, according to results from the Phase IIb… Read More

#Cancer Research #News #Trending News

#AACR 2023 #Cancer #Cancer immunotherapy #Cancer research #Oncology #Therapeutics

Eight announcements to expect at AACR 2023   

The American Association for Cancer Research (AACR) Annual Meeting is taking place at the Orange County Convention Center in Orlando, Florida from April 14-19, 2023. As the theme, Advancing the Frontiers of Cancer Science and Medicine, suggests, a number of announcements, results and presentations will take place… Read More

#News